Cargando…
Relative safety profiles of high dose statin regimens
Recent clinical trials recommend achieving a low-density lipoprotein cholesterol level of <100 mg/dl in high-risk and <70 mg/dl in very high risk patients. To attain these goals, however, many patients will need statins at high doses. The most frequent side effects related to the use of statin...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515413/ https://www.ncbi.nlm.nih.gov/pubmed/18827903 |
_version_ | 1782158423879581696 |
---|---|
author | Escobar, Carlos Echarri, Rocio Barrios, Vivencio |
author_facet | Escobar, Carlos Echarri, Rocio Barrios, Vivencio |
author_sort | Escobar, Carlos |
collection | PubMed |
description | Recent clinical trials recommend achieving a low-density lipoprotein cholesterol level of <100 mg/dl in high-risk and <70 mg/dl in very high risk patients. To attain these goals, however, many patients will need statins at high doses. The most frequent side effects related to the use of statins, myopathy, rhabdomyolysis, and increased levels of transaminases, are unusual. Although low and moderate doses show a favourable profile, there is concern about the tolerability of higher doses. During recent years, numerous trials to analyze the efficacy and tolerability of high doses of statins have been published. This paper updates the published data on the safety of statins at high doses. |
format | Text |
id | pubmed-2515413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-25154132008-10-01 Relative safety profiles of high dose statin regimens Escobar, Carlos Echarri, Rocio Barrios, Vivencio Vasc Health Risk Manag Review Recent clinical trials recommend achieving a low-density lipoprotein cholesterol level of <100 mg/dl in high-risk and <70 mg/dl in very high risk patients. To attain these goals, however, many patients will need statins at high doses. The most frequent side effects related to the use of statins, myopathy, rhabdomyolysis, and increased levels of transaminases, are unusual. Although low and moderate doses show a favourable profile, there is concern about the tolerability of higher doses. During recent years, numerous trials to analyze the efficacy and tolerability of high doses of statins have been published. This paper updates the published data on the safety of statins at high doses. Dove Medical Press 2008-06 2008-06 /pmc/articles/PMC2515413/ /pubmed/18827903 Text en © 2008 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Escobar, Carlos Echarri, Rocio Barrios, Vivencio Relative safety profiles of high dose statin regimens |
title | Relative safety profiles of high dose statin regimens |
title_full | Relative safety profiles of high dose statin regimens |
title_fullStr | Relative safety profiles of high dose statin regimens |
title_full_unstemmed | Relative safety profiles of high dose statin regimens |
title_short | Relative safety profiles of high dose statin regimens |
title_sort | relative safety profiles of high dose statin regimens |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515413/ https://www.ncbi.nlm.nih.gov/pubmed/18827903 |
work_keys_str_mv | AT escobarcarlos relativesafetyprofilesofhighdosestatinregimens AT echarrirocio relativesafetyprofilesofhighdosestatinregimens AT barriosvivencio relativesafetyprofilesofhighdosestatinregimens |